Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SHARIQ I CHUDHRI

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1710277751
CMS profile
810598
Location
FORT WORTH, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$9,628.63

199 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $5,200.00 1
Food and Beverage $4,420.40 197
Education $8.23 1

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 4; records 51–100 of 199 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SHARIQ I CHUDHRI

NPI 1710277751 · CMS profile ID 810598

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

FORT WORTH, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 199 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1710277751?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SHARIQ I CHUDHRI, NPI 1710277751, CMS profile ID 810598. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 199 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1710277751?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). SHARIQ I CHUDHRI, NPI 1710277751, CMS profile ID 810598. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 199 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1710277751?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
SHARIQ I CHUDHRI, NPI 1710277751, CMS profile ID 810598, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 199 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1710277751?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

199 matching records · $9,628.63 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 199 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 199.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Kiniksa Pharmaceuticals International, plc $22.7509/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154864117 CMS
Amgen Inc. $22.2209/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115509313 CMS
ABBVIE INC. $1.8608/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103471689 CMS
ABBVIE INC. $18.5908/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103471691 CMS
ANI Pharmaceuticals, Inc. $14.9708/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1091141648 CMS
Amgen Inc. $9.8508/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115509200 CMS
Amgen Inc. $137.6108/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115509212 CMS
Organon Llc $14.7508/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136199378 CMS
Amgen Inc. $32.5908/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117527379 CMS
Novartis Pharmaceuticals Corporation $17.4708/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086764049 CMS
Amgen Inc. $20.9308/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115509447 CMS
GENZYME CORPORATION $43.2808/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139800920 CMS
UCB, Inc. $35.6308/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143048924 CMS
ANI Pharmaceuticals, Inc. $7.6308/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1091135691 CMS
UCB, Inc. $27.4508/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143048922 CMS
GlaxoSmithKline, LLC. $24.1208/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116569029 CMS
ABBVIE INC. $32.4808/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103471687 CMS
Novartis Pharmaceuticals Corporation $14.8008/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086764041 CMS
UCB, Inc. $36.1908/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143048920 CMS
Amgen Inc. $26.9608/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115509303 CMS
Novartis Pharmaceuticals Corporation $6.4808/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086764039 CMS
UCB, Inc. $42.8008/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143048918 CMS
Octapharma USA, Inc. $24.7108/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142313334 CMS
Amgen Inc. $25.6407/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115509295 CMS
ABBVIE INC. $12.0407/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103471683 CMS
ABBVIE INC. $1.8107/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103471685 CMS
Janssen Biotech, Inc. $13.7107/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078716443 CMS
Teva Pharmaceuticals USA, Inc. $19.0507/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151591713 CMS
Alvogen Inc $17.0807/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137623959 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $29.2507/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118122805 CMS
Janssen Biotech, Inc. $13.9507/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078713721 CMS
Organon Llc $14.6107/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136199376 CMS
Amgen Inc. $25.5607/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115509434 CMS
ABBVIE INC. $17.4507/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103471681 CMS
ABBVIE INC. $28.5407/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103471679 CMS
E.R. Squibb & Sons, L.L.C. $21.7707/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101219156 CMS
Novartis Pharmaceuticals Corporation $18.7507/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086764037 CMS
GlaxoSmithKline, LLC. $18.9206/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116223308 CMS
ABBVIE INC. $22.5206/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103471677 CMS
Janssen Biotech, Inc. $21.2306/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078715793 CMS
UCB, Inc. $35.9406/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143048916 CMS
ANI Pharmaceuticals, Inc. $15.2606/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1091151708 CMS
ANI Pharmaceuticals, Inc. $3.6906/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1091132691 CMS
GENZYME CORPORATION $30.0406/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139800880 CMS
ABBVIE INC. $22.8706/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103471675 CMS
Janssen Biotech, Inc. $5.0306/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078714030 CMS
Fresenius Kabi USA, LLC $27.4406/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146945645 CMS
Novartis Pharmaceuticals Corporation $5.8606/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086764035 CMS
Fresenius Kabi USA, LLC $19.5206/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146945641 CMS
Novartis Pharmaceuticals Corporation $6.2906/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086764033 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $283.75 11
PY2020 $89.75 2
PY2021 $127.64 4
PY2022 $723.64 34
PY2023 $714.28 33
PY2024 $9,628.63 199
PY2025 $5,447.11 202

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $138,908.61 89
PY2024 Recipient $20,014.46 2
PY2024 Principal investigator $20,335.44 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

89 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ARGENX US, INC. $4,402.00 12/24/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146498
Principal investigator 1 ARGENX US, INC. $4,402.00 12/24/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146503
Principal investigator 1 ARGENX US, INC. $4,402.00 12/24/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146507
Principal investigator 1 ARGENX US, INC. $4,402.00 12/24/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146511
Principal investigator 1 ARGENX US, INC. $4,402.00 12/24/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146515
Principal investigator 1 ARGENX US, INC. $3,000.00 12/19/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146385
Principal investigator 1 ARGENX US, INC. $900.00 12/19/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146389
Principal investigator 1 ARGENX US, INC. $178.00 12/19/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146392
Principal investigator 1 ARGENX US, INC. $85.00 12/19/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146396
Principal investigator 1 ARGENX US, INC. $99.00 12/19/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146400
Principal investigator 1 ARGENX US, INC. $162.00 12/19/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146404
Principal investigator 1 ARGENX US, INC. $128.00 12/19/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146408
Principal investigator 1 ARGENX US, INC. $128.00 12/19/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146412
Principal investigator 1 ARGENX US, INC. $128.00 12/19/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146416
Principal investigator 1 ARGENX US, INC. $128.00 12/19/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146419
Principal investigator 1 ARGENX US, INC. $162.00 12/19/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146422
Principal investigator 1 ARGENX US, INC. $8,500.00 12/19/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146427
Principal investigator 1 ARGENX US, INC. $88.00 12/19/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146430
Principal investigator 1 ARGENX US, INC. $88.00 12/19/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146434
Principal investigator 1 ARGENX US, INC. $88.00 12/19/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146438
Principal investigator 1 ARGENX US, INC. $88.00 12/19/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146442
Principal investigator 1 ARGENX US, INC. $88.00 12/19/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146446
Principal investigator 1 ARGENX US, INC. $88.00 12/19/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146449
Principal investigator 1 ARGENX US, INC. $88.00 12/19/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146453
Principal investigator 1 ARGENX US, INC. $88.00 12/19/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146457
Principal investigator 1 ARGENX US, INC. $88.00 12/19/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146461
Principal investigator 1 ARGENX US, INC. $88.00 12/19/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146464
Principal investigator 1 ARGENX US, INC. $88.00 12/19/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146469
Principal investigator 1 ARGENX US, INC. $88.00 12/19/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146473
Principal investigator 1 ARGENX US, INC. $100.00 12/19/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146476
Principal investigator 1 ARGENX US, INC. $2,034.00 12/19/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146481
Principal investigator 1 ARGENX US, INC. $100.00 12/19/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146485
Principal investigator 1 ARGENX US, INC. $100.00 12/19/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146489
Principal investigator 1 ARGENX US, INC. $100.00 12/19/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146494
Principal investigator 1 ARGENX US, INC. $53.00 12/19/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146518
Principal investigator 1 ARGENX US, INC. $664.00 12/19/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146522
Principal investigator 1 ARGENX US, INC. $332.00 12/19/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146527
Principal investigator 1 ARGENX US, INC. $332.00 12/19/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146530
Principal investigator 1 ARGENX US, INC. $332.00 12/19/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146534
Principal investigator 1 ARGENX US, INC. $332.00 12/19/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146538
Principal investigator 1 ARGENX US, INC. $910.00 12/19/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146541
Principal investigator 1 ARGENX US, INC. $42.00 12/19/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146544
Principal investigator 1 ARGENX US, INC. $375.00 12/19/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146549
Principal investigator 1 ARGENX US, INC. $176.00 12/19/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146553
Principal investigator 1 ARGENX US, INC. $176.00 12/19/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146555
Principal investigator 1 ARGENX US, INC. $600.00 12/19/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146560
Principal investigator 1 ARGENX US, INC. $256.00 12/19/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146564
Principal investigator 1 ARGENX US, INC. $2,178.00 12/19/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146568
Principal investigator 1 ARGENX US, INC. $149.00 12/19/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146572
Principal investigator 1 ARGENX US, INC. $324.00 12/19/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146574
Principal investigator 1 ARGENX US, INC. $89.00 12/19/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146578
Principal investigator 1 ARGENX US, INC. $89.00 12/19/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146582
Principal investigator 1 ARGENX US, INC. $89.00 12/19/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146586
Principal investigator 1 ARGENX US, INC. $89.00 12/19/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146590
Principal investigator 1 ARGENX US, INC. $1,200.00 12/19/2025 Non-covered Recipient Entity
Arizona Arthritis & Rheumatology Research, PLLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237146594
Principal investigator 1 SANOFI US SERVICES INC. $5,100.00 12/15/2025 Non-covered Recipient Entity
Arizona Arthritis Rheumatology Research PLLC
A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis No dispute reported 06/30/2026 1226083219
Principal investigator 1 SANOFI US SERVICES INC. $5,071.35 12/08/2025 Non-covered Recipient Entity
Arizona Arthritis Rheumatology Research PLLC
A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis No dispute reported 06/30/2026 1226083199
Principal investigator 1 SANOFI US SERVICES INC. $4,693.00 12/08/2025 Non-covered Recipient Entity
Arizona Arthritis Rheumatology Research PLLC
Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study No dispute reported 06/30/2026 1226083204
Principal investigator 1 SANOFI US SERVICES INC. $1,200.00 12/08/2025 Non-covered Recipient Entity
Arizona Arthritis Rheumatology Research PLLC
Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study No dispute reported 06/30/2026 1226083207
Principal investigator 1 SANOFI US SERVICES INC. $70.00 12/08/2025 Non-covered Recipient Entity
Arizona Arthritis Rheumatology Research PLLC
Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study No dispute reported 06/30/2026 1226083210
Principal investigator 1 SANOFI US SERVICES INC. $9,042.80 12/08/2025 Non-covered Recipient Entity
Arizona Arthritis Rheumatology Research PLLC
Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study No dispute reported 06/30/2026 1226083215
Principal investigator 1 Eli Lilly and Company $2,225.00 11/25/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE-ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEKIZUMAB IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OVERWEIGHT OR OBESITY IN CLINICAL PRACTICE No dispute reported 06/30/2026 1187874927
Principal investigator 1 SANOFI US SERVICES INC. $600.00 09/22/2025 Non-covered Recipient Entity
Arizona Arthritis Rheumatology Research PLLC
A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis No dispute reported 06/30/2026 1226083184
Principal investigator 1 ARGENX US, INC. $56.40 08/04/2025 Non-covered Recipient Entity
AARA Clinical Research
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144605
Principal investigator 1 ARGENX US, INC. $66.25 08/04/2025 Non-covered Recipient Entity
AARA Clinical Research
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144609
Principal investigator 1 ARGENX US, INC. $2.80 08/04/2025 Non-covered Recipient Entity
AARA Clinical Research
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144613
Principal investigator 1 ARGENX US, INC. $382.00 08/04/2025 Non-covered Recipient Entity
AARA Clinical Research
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144617
Principal investigator 1 ARGENX US, INC. $103.50 08/04/2025 Non-covered Recipient Entity
AARA Clinical Research
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144620
Principal investigator 1 ARGENX US, INC. $258.00 06/18/2025 Non-covered Recipient Entity
AARA Clinical Research
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144458
Principal investigator 1 ARGENX US, INC. $573.00 06/18/2025 Non-covered Recipient Entity
AARA Clinical Research
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144463
Principal investigator 1 ARGENX US, INC. $238.75 06/18/2025 Non-covered Recipient Entity
AARA Clinical Research
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144466
Principal investigator 1 ARGENX US, INC. $1.75 06/18/2025 Non-covered Recipient Entity
AARA Clinical Research
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144471
Principal investigator 1 ARGENX US, INC. $517.50 06/18/2025 Non-covered Recipient Entity
AARA Clinical Research
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144475
Principal investigator 1 ARGENX US, INC. $85.40 06/18/2025 Non-covered Recipient Entity
AARA Clinical Research
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144478
Principal investigator 1 ARGENX US, INC. $159.00 06/18/2025 Non-covered Recipient Entity
AARA Clinical Research
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144484
Principal investigator 1 ARGENX US, INC. $668.50 06/18/2025 Non-covered Recipient Entity
AARA Clinical Research
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144488
Principal investigator 1 ARGENX US, INC. $35.80 06/18/2025 Non-covered Recipient Entity
AARA Clinical Research
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144492
Principal investigator 1 ARGENX US, INC. $21.35 06/18/2025 Non-covered Recipient Entity
AARA Clinical Research
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144497
Principal investigator 1 ARGENX US, INC. $214.80 06/18/2025 Non-covered Recipient Entity
AARA Clinical Research
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144501
Principal investigator 1 ARGENX US, INC. $5.25 06/18/2025 Non-covered Recipient Entity
AARA Clinical Research
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144505
Principal investigator 1 ARGENX US, INC. $75.20 06/18/2025 Non-covered Recipient Entity
AARA Clinical Research
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144508
Principal investigator 1 ARGENX US, INC. $7.70 06/18/2025 Non-covered Recipient Entity
AARA Clinical Research
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144511
Principal investigator 1 SANOFI US SERVICES INC. $21,550.00 06/16/2025 Non-covered Recipient Entity
Arizona Arthritis Rheumatology Research PLLC
A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis No dispute reported 06/30/2026 1226083157
Principal investigator 1 SANOFI US SERVICES INC. $34.81 04/07/2025 Non-covered Recipient Entity
Arizona Arthritis Rheumatology Research PLLC
Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study No dispute reported 06/30/2026 1226083097
Principal investigator 1 SANOFI US SERVICES INC. $39.60 04/07/2025 Non-covered Recipient Entity
Arizona Arthritis Rheumatology Research PLLC
Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study No dispute reported 06/30/2026 1226083105
Principal investigator 1 SANOFI US SERVICES INC. $58.00 04/07/2025 Non-covered Recipient Entity
Arizona Arthritis Rheumatology Research PLLC
Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study No dispute reported 06/30/2026 1226083109
Principal investigator 1 SANOFI US SERVICES INC. $600.00 04/07/2025 Non-covered Recipient Entity
Arizona Arthritis Rheumatology Research PLLC
Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study No dispute reported 06/30/2026 1226083113
Principal investigator 1 Eli Lilly and Company $504.10 03/24/2025 Non-covered Recipient Entity
AARA CLINICAL RESEARCH
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187875731
Principal investigator 1 Eli Lilly and Company $36,762.00 02/25/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187876057